Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 9/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.39 |
| ▸ | MMP9 | P14780 | 2/20 | 0.39 |
| ▸ | AOC2 | O75106 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | F13A1 | P00488 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GRK2 | P25098 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448329 | 0.77 | KMT2A (0.64) | LTA4HKMT2AMMP2MMP9CA1 | |
| SCHEMBL3448327 | 0.77 | KMT2A (0.64) | LTA4HKMT2AMMP2MMP9CA1 | |
| Hydrochloric Acid SCHEMBL23834278 | 0.76 | KMT2A (0.62) | LTA4HKMT2AMMP2MMP9CA1 | |
| SCHEMBL20995305 | 0.75 | LTA4H (1.00) | LTA4H | |
| SCHEMBL20995304 | 0.75 | LTA4H (1.00) | LTA4H | |
| SCHEMBL11651630 | 0.75 | KMT2A (0.50) | KMT2AJAK2MMP2MMP9CA1 | |
| SCHEMBL7711811 | 0.75 | KMT2A (0.50) | KMT2AMMP2MMP9CA1CA2 | |
| SCHEMBL11651627 | 0.75 | KMT2A (0.50) | KMT2AJAK2MMP2MMP9CA1 | |
| SCHEMBL5497956 | 0.74 | KMT2A (0.49) | KMT2AMMP2MMP9CA1CA2 | |
| SCHEMBL28103437 | 0.74 | KMT2A (0.49) | KMT2AJAK2MMP2MMP9CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551608-A1 | PENDANT AMINES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | Celtaxsys Inc. (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20190161437-A1 | PENDANT AMINES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS INC (US) | 2019-05-30 | — | — | US | disclosed |
| US-10202334-B2 | Pendant amines and derivatives as inhibitors of leukotriene A4 hydrolase | CELTAXSYS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| WO-2018107167-A1 | PENDANT AMINES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELTAXSYS, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180162804-A1 | PENDANT AMINES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | CELLTAXIS, LLC | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162804-A1 | PENDANT AMINES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KMT2A 2875/4885JAK2 2426/4885 |
| US-10202334-B2 | Pendant amines and derivatives as inhibitors of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | LTA4H 1/4885KMT2A 2875/4885JAK2 2426/4885 |
| US-20190161437-A1 | PENDANT AMINES AND DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | LTA4H 1/4885KMT2A 3232/4885JAK2 2462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.